The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | JAK inhibition in MF: monotherapy versus combination treatment
Harinder Gill, MBBS, PDipID, MD, MRCP, FRCPath, FHKCP, FHKAM, The University of Hong Kong, Hong Kong, China, discusses JAK inhibitors as monotherapy or in combination to treat patients with myelofibrosis (MF). He emphasizes the importance of individualized JAK inhibitor selection guided by patient profiles, while ongoing trials seek to identify patient populations that will respond best to monotherapy or combination treatment to allow for a personalized therapeutic approach. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: BMS, Pfizer, GSK, Novartis, PharmaEssentia
Conference support: Pfizer, Novartis, PharmaEssentia
Research Funding: Imago BioSciences, Inc. (a subsidiary of Merck & Co., Inc.), Novartis, PharmaEssentia
